Pulmatrix, Inc. (PULM): Price and Financial Metrics


Pulmatrix, Inc. (PULM)

Today's Latest Price: $1.43 USD

0.02 (-1.27%)

Updated Jan 28 10:31am

Add PULM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 488 in Biotech

See all "A" rated Strong Buy stocks

PULM Stock Summary

  • With a year-over-year growth in debt of 270.84%, Pulmatrix Inc's debt growth rate surpasses 94.33% of about US stocks.
  • As for revenue growth, note that PULM's revenue has grown 97.9% over the past 12 months; that beats the revenue growth of 94.63% of US companies in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PULM comes in at -42.05% -- higher than that of merely 6.68% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Pulmatrix Inc are AGTC, PIRS, VIE, CBIO, and ACIU.
  • Visit PULM's SEC page to see the company's official filings. To visit the company's web site, go to www.pulmatrix.com.

PULM Stock Price Chart Interactive Chart >

Price chart for PULM

PULM Price/Volume Stats

Current price $1.43 52-week high $2.06
Prev. close $1.45 52-week low $0.90
Day low $1.40 Volume 180,455
Day high $1.46 Avg. volume 1,149,412
50-day MA $1.29 Dividend yield N/A
200-day MA $1.35 Market Cap 49.26M

Pulmatrix, Inc. (PULM) Company Bio


Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The company was founded in 2003 and is based in Lexington, Massachusetts.


PULM Latest News Stream


Event/Time News Detail
Loading, please wait...

PULM Latest Social Stream


Loading social stream, please wait...

View Full PULM Social Stream

Latest PULM News From Around the Web

Below are the latest news stories about Pulmatrix Inc that investors may wish to consider to help them evaluate PULM as an investment opportunity.

Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its Q3 2020 financial results and provides a business update.

Yahoo | November 12, 2020

Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, with Partner Sensory Cloud

LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced marketing and…

PR Newswire | October 21, 2020

Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne Particles

LEXINGTON, Mass., Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the publication of…

PR Newswire | September 30, 2020

Pulmatrix Strengthens Board of Directors with Appointment of Todd Bazemore

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Todd Bazemore, a biopharmaceutical executive with significant experience in respiratory diseases, rare diseases, business development, and capital markets, to its Board of Directors, effective October 1, 2020.

Yahoo | September 29, 2020

Pulmatrix Reports Progress on Product Pipeline

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, provides an update on product pipeline.

Yahoo | September 22, 2020

Read More 'PULM' Stories Here

PULM Price Returns

1-mo 23.28%
3-mo 27.68%
6-mo 8.33%
1-year -21.43%
3-year -92.59%
5-year -94.98%
YTD 20.17%
2020 38.37%
2019 -64.17%
2018 -82.98%
2017 138.98%
2016 -85.95%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8716 seconds.